43P MIDRIX4-LUNG

MIDRIX (MPLA-Interferon-activated denDRItic cell vaXine) is an autologous mRNA-dendritic cell-based therapy that can elicit robust tumor-antigen specific cytotoxic T-cell responses and strong type 1 T-helper polarization. MIDRIX4-LUNG specifically targets 4 highly cancer-restricted antigens (MAGE-A3, PRAME, HORMAD1 and LEMD1) that, when combined, cover ≥90% of all NSCLC cases. 

During ELCC 2025, Dr Dieters Stevens (Ghent University Hospital) presented the results of a first-in-human, phase 1a open-label, single center, intra-patient dose escalation trial (NCT04082182) assessing the safety, feasibility and clinical activity of MIDRIX4-LUNG as monotherapy in heavily pre-treated metastatic NSCLC patients. 

First, the poster learned that the production and administration of this cellular therapy is feasible in this difficult and heavily pre-treated patient population. Furthermore, no dose-limiting toxicity was observed. Finally, the cancer vaccine proved to be associated with encouraging clinical and immunological outcomes, supporting its further development.